Skip to main content

C. R. Bard Value Stock - Dividend - Research Selection

Bard C R INC

ISIN: US0673831097, WKN: 856332

Market price date: 30.11.-0001
Market price: 0,00 USD


Bard C R INC Fundamental data and company key figures of the share

Annual reports in USD
Key figures 13-02-2017
Cash flow
Net operating cash flow 546.600.000
Capital Expenditures -101.200.000
Free cash flow 445.400.000
Balance sheet
Total Equity 1.675.100.000
Liabilities & Shareholders equity 5.306.100.000
Income statement
Net income 531.400.000
Eps (diluted) 7,030
Diluted shares outstanding 75.200.000
Net sales/revenue 3.714.000.000

Fundamental ratios calculated on: 30-11--0001

Ratios
Key figures 30-11--0001
Cash flow
P/C 0,00
   
P/FC 0,00
Balance sheet
ROI0,00
ROE0,00
Income statement
P/E0,00
Div. Yield0,00%
P/B0,00
P/S0,00


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolBCR
Market Capitalization24.909.248.512,00 USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internetwww.crbard.com


Description of the company

C. R. Bard, Inc. (Bard) is engaged in the design, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. As of December 31, 2011, the Company sold a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis. The Company participates in the markets for vascular, urology, oncology and surgical specialty products. Bard also has a product group of other products. Through subsidiaries and a joint venture, Bard markets its products to customers in over 100 countries outside the United States. The Company's principal international markets were in Europe and Japan as of December 31, 2011. On November 10, 2011, Bard acquired Medivance, Inc. On December 16, 2011, the Company acquired Lutonix, Inc.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.crbard.com


NEWS